Kiromic BioPharma, Inc. stock is up 403.33% since 30 days ago. The next earnings date is Apr 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 December’s closed higher than November.
Kiromic BioPharma focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University.